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While nonmyeloablative peripheral blood stem cell
transplantation (NST) has shown efﬁcacy against several
solid tumors, it is untested in nasopharyngeal cancer
(NPC). In a phase II clinical trial, 21 patients with
pretreated metastatic NPC underwent NST with sibling
PBSC allografts, using CY conditioning, thymic irradia-
tion and in vivo T-cell depletion with thymoglobulin.
Stable lymphohematopoietic chimerism was achieved in
most patients and prophylactic CYA was tapered at a
median of day þ30. Seven patients (33%) showed partial
response and three (14%) achieved stable disease. Four
patients were alive at 2 years and three showed prolonged
disease control of 344, 525 and 550 days. With a median
follow-up of 209 (4–1147) days, the median PFS was 100
days (95% conﬁdence interval (CI), 66–128 days), and
median OS was 209 days (95% CI, 128–236 days).
Patients with chronic GVHD had better survival—median
OS 426 days (95% CI, 194–NE days) vs 143 days (95% CI,
114–226 days) (P¼0.010). Thus, NST may induce mean-
ingful clinical responses in patients with advanced NPC.
Bone Marrow Transplantation (2011) 46, 573–579;
doi:10.1038/bmt.2010.161; published online 26 July 2010
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Introduction
Nasopharyngeal carcinoma (NPC) is endemic in southern
China and Southeast Asia and long-term survival for
patients with advanced NPC remains poor, despite the use
of salvage chemotherapy agents.
1–3 Molecular targeted
therapies have not yet achieved signiﬁcant beneﬁt against
NPC. Thus, novel approaches are urgently needed. Because
NPC in Asia is almost universally associated with EBV,
and viral oncoproteins (EBNA1, LMP1 and LMP2) are
expressed by tumor cells, immunotherapy represents a
promising therapeutic strategy.
4–6 Studies using adoptively
transferred EBV-speciﬁc cytotoxic T cells (CTLs) in NPC
have shown clinical responses in patients;
7–9 however, their
overall efﬁcacy is modest, especially in patients with
metastatic and/or bulky disease.
Nonmyeloablative peripheral blood stem cell transplant-
ation (NST) may present another immunotherapeutic
approach for patients with advanced stage NPC. Through
a potent graft-vs-tumor (GVT) effect,
10 NST has shown
some efﬁcacy against a range of solid tumors including
renal cell, breast and colon cancers.
11–17 Its role in NPC,
however, has not yet been evaluated.
To evaluate the role of NST in patients with pretreated
metastatic NPC, we conducted a prospective phase II
study. We used an NST regimen modiﬁed from Spitzer
et al.,
18 using the comparably more lymphodepleting rabbit
antithymocyte globulin, thymoglobulin, aiming to induce
stable mixed chimerism, before ﬁnal conversion to a full
donor lymphohematopoietic chimera. Single agent CYA
was tapered rapidly in our protocol and donor lymphocyte
infusions were used as needed.
Although patients in our study were heavily pretreated,
we achieved a reasonable response rate with NST, and
several patients had durable disease control.
Patients and methods
Patients
Patients o70 years and Eastern Cooperative Oncology
Group performance status (PS) of p2, metastatic NPC
who had received at least one line of salvage chemotherapy
were eligible. Patients with a left ventricular ejection
fraction of o45%, active angina pectoris, uncontrolled
arrhythmia, hypertension, severe chronic or restrictive lung
disease, or corrected diffusing capacity for carbon mon-
oxide of p50%, creatinine clearance of o50mL/min,
serum bilirubin of 42mg/100mL or ALT or AST 43 
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with active uncontrolled infection, active central nervous
system disease, human immunodeﬁciency virus and hepa-
titis B or C positive serology. Written informed consent was
obtained from all patients. This study was approved by the
institutional ethics committee of the National Cancer
Centre of Singapore.
Procedures
In dedicated HEPA-ﬁltered BMT rooms, patients received
a conditioning regimen of i.v. CY 50mg/kg/day from day
 5t o 3, a single fraction of 7Gy thymic irradiation
(unless there had been previous mediastinal radiation) on
day  1, in vivo T-cell depletion with rabbit antithymocyte
globulin (thymoglobulin; Genzyme, Cambridge, MA,
USA), at 2.5mg/kg/day initially on day  1, þ1, þ3 and
þ5 (regimen 1). This schedule was later modiﬁed to day
 1, þ1, þ2 and þ3 (regimen 2) because of secondary
graft loss in patients receiving regimen 1.
Hematopoietic SCT
Patients received unmanipulated allogeneic PBSC grafts
from their HLA-identical or single Ag-mismatch sibling
donor. Donor PBMC were collected by leukapheresis and
donor leukocyte infusion (DLIs) were considered at least 14
days after complete prophylactic CYA taper provided there
was no acute GVHD and/or if the donor T-cell chimerism
was not increasing. After the ﬁrst DLI, at a dose of 1 10
7
per kg CD3þ T cells, subsequent DLI was considered
monthly at incrementally increasing doses. Donor chimer-
ism was analyzed weekly using semiquantitative PCR
analysis, until full donor chimerism (495% of donor cells
in the mononuclear cell population) was achieved.
GVHD prophylaxis
All patients received GVHD prophylaxis of CYA (Neoral;
Novartis, Singapore) starting at 5mg/kg/day i.v. divided
into two doses from day  1 that was reduced to 3mg/kg/
day from dayþ4. Once engrafted, patients were converted
to daily oral CYA 12mg/kg, aiming for a therapeutic
trough level between 200 and 400ng/mL. In the absence of
acute GVHD, CYA was rapidly tapered.
Supportive care
Prophylactic ciproﬂoxacin, ﬂuconazole, acyclovir and
cotrimoxazole were administered as described previously.
18
For acute GVHD of Xgrade II, methylprednisolone of
2mg/kg/day was initiated. CMV infection was screened
using viral pp65 antigenemia assay weekly after hospital
discharge until day þ100. Pre-emptive i.v. ganciclovir was
administered according to institutional practice.
Treatment-related toxicities and GVHD
Toxicities were graded according to National Cancer
Institute Common Toxicity Criteria (version 3.0) and the
severity of acute GVHD according to the International
Bone Marrow Transplant Registry criteria and post-DLI
acute and chronic GVHD by the common criteria.
19
Immunophenotyping T-cell subpopulations
Peripheral blood was collected from 20 evaluable NPC
patients pre-NST and serially up to 1-year post-NST, and
from 20 healthy volunteers to serve as normal controls.
Immunophenotyping of human T lymphocytes was per-
formed by multicolor ﬂow cytometric analysis by FACS-
Calibur (Becton Dickinson, San Jose, CA, USA) to
determine the levels of speciﬁc functional T-cell subsets,
such as naive, memory/effector T cells and regulatory T
(Treg) cells.
20
Monitoring cell-free EBV DNA in plasma
DNA was extracted from plasma samples collected at
monthly intervals. Real-time PCR with EBV-speciﬁc probe
and primer sets targeted at the Epstein-Barr Nuclear
Antigen region was performed as previously described.
21
Statistical analysis
The interval of PFS was calculated from the date of
transplantation to the ﬁrst documentation of disease
progression or death from any cause, or last follow-up;
and OS duration from the date of transplantation to the
ﬁrst documentation of death from any cause, or last follow-
up. Duration of response was measured from date of ﬁrst
objective RECIST response to date of disease progression
or death, whichever earlier. Time to response was measured
from the date of transplantation to the ﬁrst documentation
of response.
Pearson w
2-test or Fisher’s exact test was used to test
the association between categorical variables, whereas
Mann–Whitney U-test was used to test the difference of
continuous variables. Best overall tumor response rate was
summarized with 95% conﬁdence interval using the Wilson
method.
22 Survival and response curves were estimated by
the Kaplan–Meier method and comparisons between
curves were tested by log-rank test.
Results
Patient characteristics
Between July 2002 and July 2007, 59 advanced NPC
patients and their siblings were screened and HLA-typed.
Twenty-six patients with histologically conﬁrmed meta-
static NPC and available HLA-matched sibling donor
allografts (n¼24) or an HLA one-Ag mismatched donor
allograft (n¼2) were accrued. Only 21 patients eventually
received NST due to rapid progressive disease in 5 patients.
In 2003, the severe acute respiratory syndrome epidemic
halted accrual of patients for almost a year.
Median age (n¼21) was 48 (34–57) years, and patients
had received a median of two previous chemotherapy
regimens (1–8) with a median of four (2–8) chemotherapy
agents. All patients had extensive metastases, with a
median of four (2–5) organ sites and 17 had previous
progressive disease (Table 1). Seventeen patients (81%)
had performance status (PS) of 0–1 and four (19%) had a
PS of 2.
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The median hospitalization for NST was 25 (12–90) days
and the median PBSC dose infused was 5.25 10
6 (2.42–
10.18 10
6) CD34þ PBSC per kg. Median time to
engraftment was 12 (9–20) days. Three patients (15%)
developed mild engraftment syndrome (pgrade II). Four
patients (20%) had secondary engraftment loss, under
regimen 1, whereas no patient under regimen 2 experienced
graft loss (P¼0.087). One patient on regimen 1 was given
i.v. CY before third DLI to augment donor chimerism.
Patients with mixed chimerism who did not have acute
GVHD underwent rapid CYA taper. The median time to
complete removal of CsA for 19 evaluated patients was on
day þ30 (day þ16 to þ42). CYA was subsequently
restarted for the treatment of either acute or chronic
GVHD in 10 patients, with patients receiving concurrent
corticosteroids.
The median level of donor chimerism among patients
who had achieved stable mixed chimerism was 50% at day
þ100 and 95% at 6 months post-NST. Sixteen patients
received DLIs. The median number of DLIs administered
per patient was 2 (1–6), and the mean dose at each
administration per patient was 1.53±0.43 10
7 CD3
þ T
cells per kg. Immune reconstitution of CD3
þ, CD4
þ
and CD8
þ T-cell populations post-NST is outlined in
Supplementary Figure 1A and Treg cell data are provided
in Supplementary Figure 1B. Patients on study had
higher baseline Treg cells (9.41%) compared to normal
controls (P¼0.009) though there was no difference in
pre-NST CD4
þ Treg numbers between responders and
nonresponders.
Transplant mortality and adverse events
Two patients died within 100 days of transplant, one of
acute GVHD on day þ91 (patient 5), and one of acute
pulmonary embolism on day þ4 (patient 21). Bacterial
infections (grades III, IV and V) constituted the commonest
complication, occurring in seven patients (Table 2). In most
instances, sepsis occurred within 100 days of NST, and was
effectively treated with i.v. antibiotics. One patient died
from a strongyloides infection on day þ137 post-NST.
One patient developed CMV retinitis and was successfully
treated with ganciclovir.
Grade II–IV acute GVHD occurred in ﬁve patients
(25%), and was controllable with standard immunosup-
pressive agents in all except in one patient who died on day
þ91, following a second DLI. Chronic GVHD (all limited)
was diagnosed in six patients (30%), and only one patient
required prolonged CYA treatment.
Table 1 Characteristics of and treatments received by patients
ID Age
(year)
Sex HLA
typing
PS No. of
disease
sites
Site of disease Total no.
of CT
lines
Previous
RT
status
Disease
status at
accrual
Best
overall
response
Time to
tumor
response
(days)
Duration
of response
(days)
Time to
tumor
progression
(days)
Survival
time
(days)
1
a 37 M 6/6 1 4 PNS, bone, lung, LN 3 Y PD NE 186 186
b
2
a 49 M 6/6 2 3 Liver, bone, LN 1 Y PD PD 84 117
b
3
a 54 M 6/6 1 2 Liver, LN 1 N SD PD 94 754
b
4
a 34 F 6/6 1 2 Lungs, LN 2 Y SD PR 41 119 160 194
b
5
a 38 M 6/6 0 4 Pleural, lung, spleen, bone 5 Y PR NE 91 91
c
6
a 57 M 6/6 1 3 LN, lung, liver 1 Y PD SD 110 513
b
7
a 44 F 6/6 0 3 LN, lung, bone 1 Y PD PR 662 211 118 1014
b
8
a 51 M 5/6 1 4 Liver, lung, bone, LN 1 Y SD NE 54
d 226
b
9
a 45 F 6/6 1 4 PNS, cx-LN, retroph-LN, bone 3 Y PD SD 344 426
b
10
a 43 M 6/6 1 3 Lung, bone, liver 3 Y PD PD 57 236
b
11
e 49 F 6/6 2 4 Lung, bone, liver, pleural 3 Y PD PD 72 107
b
12
e 40 M 6/6 0 3 Liver, LN, PNS 3 Y PD PD 57 211
b
13
e 51 M 6/6 1 3 PNS, liver, lung 2 Y PD PR 36 64 100 209
b
14
e 46 M 6/6 2 4 LN, pleural, bone, dermis 8 Y PD PR 57 71 128 128
f
15
e 48 F 6/6 1 4 Liver, LN, lung, bone 2 Y PD PD 58 114
b
16
e 49 M 6/6 1 4 Lung, BM, bone, LN 1 Y PD PR 129 396 525 774
b
17
e 55 M 6/6 1 5 Liver, bone, LN, lung, spleen 2 Y PD PD 66 210
b
18
e 45 M 6/6 1 2 Lung, LN 2 Y PD PR 26 77 103 1147
g
19
e 49 M 5/6 1 4 PNS, LN, bone, liver 3 Y PD PR 101 36 137 137
f
20
e 48 F 6/6 2 4 SVCO, lung, liver, LN 5 Y PD SD 142
d 143
b
21
e 44 M 6/6 1 3 LN, liver, bone 3 Y PD NE 4 4
h
Abbreviations: CT¼chemotherapy; cx¼cervical; F¼female; LN¼lymph nodes; M¼male; N¼no; NE¼not evaluable; PD¼progressive disease;
PNS¼posterior nasal space; PR¼partial response; PS¼performance status according to Eastern Cooperative Oncology Group criteria;
retroph¼retropharyngeal; RT¼radiotherapy; SD¼stable disease; SVCO¼superior vena cava obstruction; Y¼yes.
Note: Time to tumor response, time to tumor progression and survival time were calculated from the date of transplantation.
aTreated with regimen 1: thymoglobulin at 2.5mg/kg/day on day  1, +1, +3 and +5.
bDied due to progressive disease.
cDied due to acute GVHD.
dDisease progression detected during clinical examination.
eTreated with regimen 2: thymoglobulin at 2.5mg/kg/day on day  1, +1, +2 and +3.
fDied due to infection.
gAlive.
hDied due to pulmonary embolism.
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Seven patients (33%) achieved partial responses (PR) and
three (14%) achieved stable disease, yielding an overall
response rate of 47% (Supplementary Figure 2). The
median time to PR was 57 (26–662) days and the median
duration of PR was 77 (36–396) days. Late responses
(4day þ100) were observed in three patients (patients 7,
16 and 19) coincident with rising donor chimerism. Patients
with GVHD had a much higher likelihood of response than
patients without GVHD (P¼0.004, Figure 1a). Serial
evaluation of EBV DNA levels were performed in 11
patients and showed a strong correlation to the observed
clinical responses (Supplementary Table 1).
PFS and OS
At the time of analysis, only one patient was alive. With a
median follow-up of 209 (4–1147) days, the estimated
median PFS was 100 (95% CI, 66–128) days (Figure 1b)
and the 1-year PFS rate was 5% (s.e., 0.047). Two patients
showed prolonged disease control of 344 and 525 days and
a third had a second PFS of 550 days.
Patient 7, a lady with progressive lung, nodal, and bone
metastases pre-NST achieved brief tumor shrinkage post-
NST but progressed on day þ118. Following limited
chronic GVHD on day þ202, she achieved stable disease
for approximately 3 months before progressing again. Five
DLIs were then administered (Supplementary Figure 2).
Although her disease continued to regress on CT scans,
objective PR did not occur until much later on day þ662.
Her response duration was 211 days and the duration of
her second PFS was 550 days.
Patient 16 experienced the longest response duration (396
days), even though he had entered the study with an
extremely aggressive disease and evidence of impending
BM failure. Pre-NST, he was symptomatic with worsening
dyspnea and intense bone pain despite NSAID and opioid
analgesia. He achieved tumor shrinkage of 34% on day
þ129 when donor chimerism increased from 25 to 87%
that correlated with a decreasing EBV DNA titer (Figure 2).
Upon onset of limited chronic GVHD, his tumor continued
to shrink further, and regressed once again when donor
chimerism reached 100% (Figure 2b). One year after NST,
he achieved PR and complete resolution of all symptoms
with signiﬁcant improvement in quality of life, and his BM
biopsy, that had still been positive at dayþ100, ﬁnally
showed no detectable NPC.
Patient 19 achieved a chimerism of 60% 6 weeks post-
NST but this decreased to 12% by day þ111. He attained
a late PR on day þ101 with a more than 75% reduction in
Table 2 Transplantation-associated adverse events
Adverse events No. of patients (%) Total
Grade III Grade IV Grade V
Bacterial sepsis
a 4 (19) 4
Bacterial pneumonia 1 (4.8) 1 (4.8) 2
Pseudomonas otitis externa 1 (4.8) 1
Candidemia 1 (4.8) 1
PCP pneumonia 1 (4.8) 1
Strongyloides superinfection 1 (4.8) 1
GVHD (fatal) 1 (4.8) 1
Massive pulmonary embolism 1 (4.8) 1
Seizure
b 1 (4.8) 1
Acute confusional state
c 2 (9.5) 2
aLine sepsis in three patients.
bHyponatremic seizures.
cSteroid induced.
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Figure 1 (a) Kaplan–Meier estimate of cumulative probability of a
response (that is, partial response, PR) in all patients and in patients with
or without GVHD. Patients in whom GVHD developed after NST had
signiﬁcantly higher probability of response. (b) Kaplan–Meier estimated
PFS. (c) Kaplan–Meier estimated OS according to chronic GVHD status.
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Bone Marrow Transplantationtumor diameter. Chimerism improved from 12 to 62.5%,
18 days after the PR that was related to mild GHVD.
The median OS for patients who underwent NST was
209 (95% CI, 128–236) days, the 1-year OS rate was 29%
(s.e., 0.099) and the 2-year OS rate was 19% (s.e., 0.088).
Patients with chronic GVHD also had much better
survival—median OS was 426 days (95% CI, 194–NE
days) vs 143 days (95%CI, 114–226 days) in patients
without chronic GVHD (P¼0.010, Figure 2c). Patients
who responded to treatment (PR or stable disease) also
had a trend toward better survival than nonresponders;
median survival time of 326 (95% CI, 136–782) days against
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Figure 2 (a) CT scan images for patient 16. The tumor masses (indicated by arrowheads) show reduction in sizes that correlates with a corresponding
increase in donor chimerism. On day þ336, patient 16 continues to show tumor response. (b) Donor lymphohematopoietic chimerism levels and tumor
diameter. (c) Serial plasma cell-free EBV DNA titer in patient 16.
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Bone Marrow Transplantation195 (95% CI, 100–235) days, respectively (univariate
P¼0.055). Responders and nonresponders were similar in
age, number of disease sites and previous chemotherapy,
although pre-NST performance status was poorer in
responders.
Discussion
We report results of the ﬁrst study exploring NST in
advanced NPC. Our results show that NST is feasible, and
may induce durable responses in subsets of patients, even in
the presence of extensive, bulky disease. In our study, we
achieved a response rate of 33% and a clinical beneﬁt of
47%, which compares well with the response rates achieved
in second- and third-line chemotherapy against NPC
(approximately 11–23%).
1–3
Our NST regimen was overall well tolerated. The
integration of thymoglobulin into the same ATG schedule
as the Spitzer regimen
18 (regimen 1) resulted in a high
incidence of secondary engraftment loss in 4 out of 10
patients. After we revised to incorporate thymoglobulin
earlier into the conditioning timeline (regimen 2), which
may have worked better to deplete host than donor
T lymphocytes, all 10 evaluable patients achieved stable
and full donor lymphohematopoietic chimerism. In our
study, engraftment syndrome occurred only in 15% of
patients and was mild, requiring no treatment, as compared
to 67% in the Boston study
18 in which some patients
required high-dose steroids for control of this syndrome.
Although our median PFS was short, PFS may under-
estimate clinical beneﬁt for several reasons. Patients may
experience late responses, which occur only after an initial
disease progression—however, because only the ﬁrst event
(progressive disease) is used to construct the Kaplan–Meier
graph, it would give the false impression of a lack of
beneﬁt. Late responses have been described in earlier NST
studies and occur typically 3–6 months post transplant,
23,24
after conversion to a full donor chimerism, although it may
be inﬂuenced by factors such as the early withdrawal of
immunosuppressants or the use of DLIs.
12 Second, patients
on NST may experience more than one response. For
example, patient 7 had 2 periods of responses—whereas her
ﬁrst PFS was 127 days, the second PFS was signiﬁcantly
longer at 550 days. Finally, NST through reconstituting the
immune system may change the biological and growth
characteristics of the disease, and thus OS (which is not
reliant on any single time point cutoff) may be a more
accurate measure of true beneﬁt.
The median OS in our NST study was 7.4 months, with
1- and 2-year OS rate of 29 and 19%, respectively, which is
comparable to the median 7–14 months OS for metastatic
NPC patients in literature.
1–3 More importantly, our
subgroup analysis indicates that chronic GVHD signiﬁ-
cantly predicted for both response and OS. This raises
questions regarding the role of mHA in mediating the GVT
effect, which could be exploited further as an antitumor
strategy.
14,25,26
Despite early prophylactic CYA taper, GVHD incidence
in our study was acceptable, largely due to the high
percentage of patients who achieved mixed chimerism by
day þ100. Still, infections were more commonly observed
in our study as compared with other NST studies.
11–13 This
may be related to xerostomia, poor dentition, chronic
sinusitis and altered mucosal barriers in our NPC patients,
most of whom had previous radiotherapy for primary
disease. Future NST studies should consider such local
immunosuppressive features when selecting patients
for NST.
In summary, our study shows that our thymoglobulin-
based NST can induce durable responses in NPC patients
and overall allow for early taper of prophylactic CYA with
acceptable GVHD rates and evidence of GVT. However
regimen-related toxicities require careful patient selection.
In the study of NST in Hodgkin’s disease, an EBV-related
tumor, better outcomes were achieved in patients with
induced remission before NST.
27 It is therefore likely that
better outcomes may have been achievable if NST were to
be performed in metastatic NPC patients who show
response to induction chemotherapy.
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